Nirsevimab effective in preventing hospitalization for RSV associated lower RTI in infants
Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection in young children and infants, leading to hospitalization.
According to a study published in the New England Journal of Medicine, Nirsevimab protected infants against hospitalization for RSV-related lower respiratory infections in conditions that approximated real-world settings.
The aim of the study was to establish safety and efficacy of nirsevimab (monoclonal antibody) in preventing hospitalizations for RSV-related lower respiratory tract infections in healthy infants.
Researchers randomly assigned 12-month-old infants or younger, born at least 29 weeks gestational age and entering their first RSV season in France, Germany, or the UK, to receive a single intramuscular injection of nirsevimab or standard care before or during the RSV season.
The primary endpoint was hospitalization for RSV-associated lower respiratory tract infection. The secondary endpoint was a very severe RSV-associated lower respiratory tract infection with an oxygen saturation of less than 90% and the need for supplemental oxygen.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.